HDAC9 and Duchenne muscular dystrophy: In summary, our findings provide compelling evidence supporting VPA as an effective adjuvant to ASO therapy, paving the way for future studies into HDAC inhibitors in exon-skipping therapies and offering new hope for improving treatments for individuals affected by DMD.